GoOn MRI: Efficacy Study of "Go On" in Magnetic Resonance Imaging (MRI) Improvement in Osteoarthritis (OA) Knee

Sponsor
Khon Kaen University (Other)
Overall Status
Completed
CT.gov ID
NCT00750724
Collaborator
(none)
60
1
2
15
4

Study Details

Study Description

Brief Summary

OA knee is a common degenerative diseases of the joint.

  • There are many methods to treat this condition.

  • Hyaluronic acid is one of the recomended treatment of OA knee.

  • There is no any study on MRI change after injection hyaluronic acid.

  • The Hypothesis is 25 mg of sodium hyaluronate (2.5 ml) would preserve the joint space in patient with osteoarthritis of the knee compared to placebo .

Condition or Disease Intervention/Treatment Phase
  • Drug: 25 mg sodium hyaluronate "GO ON"
  • Drug: normal saline,2 ml., intraarticular weekly for 5 weeks
Phase 3

Detailed Description

This will be the phase III randomized, double-blind, placebo-controlled trial of 52 weeks duration designed to evaluate the efficacy of sodium hyaluronate to placebo (saline), in adult with OA of the knee joints. Randomization will be stratified by Kellgren-Lawrence(KL) grade (garde2 or 3), by subjects X-ray. A total of 60 subjects are planed for enrollment in this study. The study will be conducted over approximately 52 weeks.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Phase 3 Study GoON and MRI Improvement in OA Knee
Study Start Date :
Jul 1, 2008
Actual Primary Completion Date :
Sep 1, 2009
Actual Study Completion Date :
Oct 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: B

2 ml of Normal saline intraarticular injection to the knee joint weekly for 5 weeks

Drug: normal saline,2 ml., intraarticular weekly for 5 weeks

Experimental: A

2 ml of 25 mg sodium hyaluronate intraarticular injection to the knee joint weekly for 5 weeks

Drug: 25 mg sodium hyaluronate "GO ON"
25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks

Outcome Measures

Primary Outcome Measures

  1. MRI will be analysed with semiquantitative whole organ scoring method (WORMS) c [6 months]

Secondary Outcome Measures

  1. WOMAC, VAS, side effects [14 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects who are capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

  • Ambulatory non pregnant females and males 40-<80 years of age.

  • Subjects who withdraw pain medication or nutritional supplements for symptom relief for OA hand for a total of at least 30 days before screening visit 0.

  • Pain at or below 40 mm on a 100 mm VAS in the index knee joints.

  • A documented diagnosis of OA of the knee joint, or meeting American College of Rheumatology (ACR) clinical criteria for classification of idiopathic (primary) OA for at least 6 months prior to screening.

  • Subject has been documented radiographic evidence of OA of the knees from the screening Visit radiograph of grade 2 or 3 according to Kellgren and Lawrence Radiographic Grading.

  • Subject has no any contraindication for MRI

  • Subject is able to understand and complete pain/function, global arthritis evaluation, and health outcome assessment.

Exclusion Criteria:
  • Subjects with history of hypersensitivity to hyaluronate.

  • Subjects with skin lesion at the knee joint.

  • A history of knee surgery within 6 months prior to screening V0.

  • Significant prior injury to the knee joint within 12 months prior to screening V0.

  • Disease of the spine or other lower extremity joints of sufficient degree to affect the knee joint.

  • Treatment with other drugs potentially affecting bone or cartilage metabolism as described below:

  • chronic systematic corticosteroids

  • Diacerin or glucosamine treatment within the last 12 months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Weerachai Kosuwon Khon Kaen Thailand 40001

Sponsors and Collaborators

  • Khon Kaen University

Investigators

  • Principal Investigator: Weerachai Kosuwon, Professor, Faculty of Medicine, Khon Kaen University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00750724
Other Study ID Numbers:
  • Faculty of Medicine, Khon Kaen
First Posted:
Sep 10, 2008
Last Update Posted:
May 26, 2010
Last Verified:
Jul 1, 2009
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 26, 2010